ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,281 to 1,300 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Comfort Talk® Training OSU vs Control OSU: No-shows in Q2FY16 (OSU)214 of 4,121

213 of 3,070

-1.7 points

-2.9 to -0.6

7,191NCT02427737

Comfort Talk and Economic Outcomes in MRI

C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic PCR Confirmed CDI Cases: Per-Protocol Population23 of 4,786

13 of 2,378

-0.1 points

-0.5 to 0.3

7,164NCT01887912

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Rivaroxaban 15 mg OD vs Acetylsalicylic Acid 100 mg OD: deaths from any cause73 of 3,562

58 of 3,559

0.4 points

-0.2 to 1.1

7,121NCT02313909

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Rivaroxaban 15 mg OD vs Acetylsalicylic Acid 100 mg OD: serious adverse events466 of 3,562

434 of 3,559

0.9 points

-0.7 to 2.4

7,121NCT02313909

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With BARC Type 2, 3, or 5141 of 3,555

250 of 3,564

-3.0 points

-4.1 to -2.0

7,119NCT02270242

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Placebo + Ticagrelor vs Aspirin + Ticagrelor: serious adverse events262 of 3,555

370 of 3,564

-3.0 points

-4.3 to -1.7

7,119NCT02270242

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Intervention Arm Stage 1 vs Intervention Arm Stage II: serious adverse events89 of 1,671

50 of 5,447

4.4 points

3.4 to 5.6

7,118NCT01864603

Sustainable East Africa Research in Community Health

aTIV (Pooled) vs Licensed TIV: serious adverse events264 of 3,545

243 of 3,537

0.6 points

-0.6 to 1.8

7,082NCT01162122

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Comfort Talk® Training OSU vs Control OSU: No-shows in Q3FY16 (OSU)220 of 4,148

215 of 2,931

-2.0 points

-3.2 to -0.9

7,079NCT02427737

Comfort Talk and Economic Outcomes in MRI

V710 60 µg vs Placebo: Number of Participants With Invasive Staphylococcus Aureus Infection27 of 3,528

31 of 3,517

-0.1 points

-0.6 to 0.3

7,045NCT00518687

Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)

V710 60 µg vs Placebo: Number of Participants With Staphylococcus Aureus Bacteremia and/or Deep Sternal Wound Infection22 of 3,528

27 of 3,517

-0.1 points

-0.6 to 0.3

7,045NCT00518687

Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)

V710 60 µg vs Placebo: Number of Participants With Surgical-site Staphylococcus Aureus Infection53 of 3,528

75 of 3,517

-0.6 points

-1.3 to -0.0

7,045NCT00518687

Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)

Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With Ischemic Episode135 of 3,524

137 of 3,515

-0.1 points

-1.0 to 0.8

7,039NCT02270242

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Placebo + Ticagrelor vs Aspirin + Ticagrelor: deaths from any cause34 of 3,524

45 of 3,515

-0.3 points

-0.8 to 0.2

7,039NCT02270242

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Nesiritide vs Placebo: Number of Patients With Renal Impairment1,032 of 3,498

968 of 3,509

1.9 points

-0.2 to 4.0

7,007NCT00475852

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Nesiritide vs Placebo: All-Cause Mortality Through Day 30126 of 3,498

141 of 3,509

-0.4 points

-1.3 to 0.5

7,007NCT00475852

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Nesiritide vs Placebo: All-Cause Mortality Through Day 180429 of 3,498

447 of 3,509

-0.5 points

-2.0 to 1.1

7,007NCT00475852

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Nesiritide vs Placebo: serious adverse events5 of 3,498

2 of 3,509

0.1 points

-0.1 to 0.3

7,007NCT00475852

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

aTIV (Pooled) vs Licensed TIV: Number of Subjects Reporting Healthcare Utilization Across Vaccine Groups275 of 3,499

289 of 3,502

-0.4 points

-1.7 to 0.9

7,001NCT01162122

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

N2O Group (FiO2 0.3) vs N2O Free Group (FiO2 0.3): Pulmonary Embolism18 of 3,483

22 of 3,509

-0.1 points

-0.5 to 0.3

6,992NCT00430989

The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=65

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02427737-68734ccf",
        "title": "Comfort Talk® Training OSU vs Control OSU: No-shows in Q2FY16 (OSU)",
        "summary": "214 of 4121 against 213 of 3070; risk difference -1.7 points, 95% interval -2.9 to -0.6; NCT02427737, Comfort Talk and Economic Outcomes in MRI",
        "record": "/library/comparisons/NCT02427737-68734ccf",
        "nct_id": "NCT02427737",
        "kind": "outcome",
        "participants": 7191,
        "risk_difference": {
          "value": -0.01745196408006342,
          "lower": -0.028919001914788224,
          "upper": -0.006341368340036936
        },
        "group_1": "214 of 4,121",
        "group_2": "213 of 3,070",
        "difference": "-1.7 points",
        "interval": "-2.9 to -0.6",
        "trial_title": "Comfort Talk and Economic Outcomes in MRI"
      },
      {
        "id": "NCT01887912-05d1270c",
        "title": "C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic PCR Confirmed CDI Cases: Per-Protocol Population",
        "summary": "23 of 4786 against 13 of 2378; risk difference -0.1 points, 95% interval -0.5 to 0.3; NCT01887912, Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",
        "record": "/library/comparisons/NCT01887912-05d1270c",
        "nct_id": "NCT01887912",
        "kind": "outcome",
        "participants": 7164,
        "risk_difference": {
          "value": -0.0006610955629276164,
          "lower": -0.004844009764276088,
          "upper": 0.0026385042778453703
        },
        "group_1": "23 of 4,786",
        "group_2": "13 of 2,378",
        "difference": "-0.1 points",
        "interval": "-0.5 to 0.3",
        "trial_title": "Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=66",
  "request_id": "WbCsG5F12xJmdMUn"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?